Page last updated: 2024-11-04

9,10-dimethyl-1,2-benzanthracene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

9,10-Dimethyl-1,2-benzanthracene: Polycyclic aromatic hydrocarbon found in tobacco smoke that is a potent carcinogen. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

7,12-dimethyltetraphene : A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6001
CHEMBL ID329673
CHEBI ID254496
MeSH IDM0023271

Synonyms (89)

Synonym
CHEMBL329673
7,12-dimethyl-benzo[a]anthracene
7,12-dimethyl-benzo[b]phenanthrene
benz(a)anthracene, 7,12-dimethyl-
9,10-dimethyl-1,2-benzanthracene
benz[a]anthracene, 7,12-dimethyl-
7,12-dimethylbenz[a]anthracene
7,12-dimethyltetraphene
7,12-dimethylbenz(a)anthracene
6,7-dimethyl-1,2-benzanthracene
9,10-dimethylbenz(a)anthracene
dimethylbenzanthrene
9,2-benzanthracene
7,12-dimethylbenzanthracene
dimethylbenz[a]anthracene
57-97-6
9,2-benzanthrazen
6,2-benzanthracene
9,10-dimethylbenz[a]anthracene
7,12-dmba
dmba
nci-c03918
nsc-408823
wln: l d6 b666j f1 g1
1,3-benzphenanthrene
7,12-dimethylbenzo[a]anthracene
wln: l d6 b666j c1 j1
nsc408823
7,2-benzanthracene
benz[a]anthracene,10-dimethyl-
NCGC00091518-01
ccris 274
einecs 200-359-5
hsdb 2938
9,10-dimethyl-1,2-benzanthrazen [german]
7,12-dimethylbenzo(a)anthracene
7,12-dimethylbenzanthrancene
rcra waste number u094
1,4-dimethyl-2,3-benzphenanthrene
nsc 408823
rcra waste no. u094
ai3-50460
brn 1912135
7,12-dimethyl-1:2-benz(a)anthracene
7,12-dimethyl-1,2-benzanthracene
7,12-dimethylbenz[a]anthracene, analytical standard
7,12-dimethylbenz[a]anthracene, >=95%
NCGC00091518-02
dmba/tpa/bpo/mnng
7,12 dimethylbenzanthracene
MLS001333155
MLS001333156
smr000857253
D0677
MLS002454381
9,10-dimethyl-1,2-benzanthrazen
chebi:254496 ,
NCGC00091518-04
NCGC00091518-07
NCGC00091518-05
NCGC00091518-03
NCGC00091518-06
C19488
cas-57-97-6
dtxsid1020510 ,
NCGC00259354-01
dtxcid70510
tox21_300500
NCGC00254337-01
tox21_201805
HMS2232O09
4-05-00-02587 (beilstein handbook reference)
f05b6s0395 ,
unii-f05b6s0395
FT-0621327
EPITOPE ID:119712
AKOS015903190
9,10-dimethyl-1,2-benzanthracene [mi]
mfcd00003600
7,12-dimethylbenz (a) ant racene
7,12-dimethylbenz[a]anthracene, >=98%
712-dimethyl-benzo[a]anthracene
7,12-dimethylbenz(a)ant racene
Q187487
T71090
dmbza
BS-43984
CS-W012561
HY-W011845

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Several phenols were examined as possible toxic metabolites of DMBA, but these were not toxic at dose levels at which DMBA kills most of the normal cells."( Biochemical basis for cytotoxicity of 7,12-dimethylbenz(a)anthracene in rat liver epithelial cells.
Dipple, A; Iype, PT; Tomaszewski, JE, 1979
)
0.26
" This is consistent with previous descriptions of a toxic effect on all ovarian components including growing and resting follicles."( Morphometric assessment of the murine ovarian toxicity of 7,12-dimethylbenz(a)anthracene.
London, SN; Mattison, DR; Miller, MM; Weitzman, GA, 1992
)
0.28
" 7,12-Dimethylbenz(a)anthracene (DMBA) and 7-hydroxymethyl-12-methylbenz(a)anthracene (7-OHM-12-MBA), but not benzo(a)pyrene (BP), selectively produce necrosis in the two inner zones of the rat adrenal cortex and are toxic to cultured rat adrenocortical cells."( Influence of effectors of prostaglandin metabolism on the toxicity induced by 7-hydroxymethyl-12-methylbenz(a)anthracene in cultured rat adrenal cells.
Hallberg, E; Rydström, J, 1990
)
0.28
" The toxic effects of chemicals arise either from the chemical itself or from metabolites."( Metabolic perspectives on in vitro toxicity tests.
Glatt, H; Oesch, F; Utesch, D, 1988
)
0.27
"Traditional methods for toxicological assessment have implicated the immune system as a frequent target organ of toxic insult following chronic exposure to certain environmental chemicals, radiation or therapeutic drugs (xenobiotics)."( Mechanisms of dimethylbenzanthracene-induced immunotoxicity.
Dean, JH; House, RV; Lauer, LD; Murray, MJ; Ward, EC, 1985
)
0.27
" The toxic effects of benzo[a]pyrene (BP) and 7,12-dimethylbenz[a]anthracene (DMBA) were studied in these two cell lines."( Cytotoxic effects and metabolism of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in duodenal and ileal epithelial cell cultures.
Isselbacher, KJ; Quaroni, A, 1981
)
0.26
" Using ACTH-induced corticosterone synthesis as an indicator of cell damage the hepatic metabolite 7-hydroxymethyl-12-methyl-benz[a]anthracene was shown to be significantly more toxic than the parent compound DMBA."( Metabolism and toxic effects of 7,12-dimethyl-benz[a]anthracene in isolated rat adrenal cells.
Hallberg, E; Rydström, J, 1983
)
0.27
"In the past several years there has been a great deal of interest in the antioxidant beta-carotene and other micronutrients for their protective potential against various toxic insults."( beta-Carotene inhibition of chemically induced toxicity in vivo and in vitro.
Kornhauser, A; Lambert, LA; Wamer, WG; Wei, RR, 1994
)
0.29
" Treatment of mice with the combination demonstrated that the marrow progenitors were protected from the toxic effects of CPA by the arotinoid."( The anti-tumor arotinoid Ro 40-8757 protects bone marrow from the toxic effects of cyclophosphamide.
Eliason, JF; Hartmann, D; Horii, I; Inoue, T; Kubota, A; Teelmann, K, 1993
)
0.29
"0159 microg/mL with UV) while CLZ was negative up to a toxic concentration of 35 microg/mL."( Photoclastogenicity-an improved protocol, its validation, and investigation of the photogenotoxicity of DMBA.
Aardema, M; Lawlor, T; Murli, H; Spicer, C, 2002
)
0.31
" In congenic mice with a low affinity AhR (AhR(d)), DMBA and BP are equally toxic to the BM whereas AhR(d) x CYP1B1-null mice are fully protected."( Bone marrow cytotoxicity of benzo[a]pyrene is dependent on CYP1B1 but is diminished by Ah receptor-mediated induction of CYP1A1 in liver.
Czuprynski, CJ; Galván, N; Jaskula-Sztul, R; Jefcoate, CR; MacWilliams, PS, 2003
)
0.32
" In conclusion, Se appears to be effective in preventing some of the adverse effects associated with DMBA."( Toxicity induced by the chemical carcinogen 7,12-dimethylbenz[a]anthracene and the protective effects of selenium in Wistar rats.
Alakavuklar, M; Canda, T; Cehreli, R; Demirkan, B; Harmancioglu, O; Kocdor, H; Kocdor, MA; Resmi, H; Sis, B; Yilmaz, O, 2005
)
0.33
" Although the methyl substitution reportedly affects their mutagenicity and tumor-initiating activity, little is known about the impact of methylation on the effects associated with activation of the aryl hydrocarbon receptor (AhR)-dependent gene expression and/or toxic events associated with tumor promotion."( Toxic effects of methylated benz[a]anthracenes in liver cells.
Krcmárr, P; Machala, M; Marvanová, S; Milcová, A; Nováková, Z; Penccíková, K; Topinka, J; Trilecová, L; Vondrácek, J, 2008
)
0.35
" All compounds, except PCB153, induced a dose-dependent increase in toxic effects."( A new spiked sediment assay using embryos of the Japanese medaka specifically designed for a reliable toxicity assessment of hydrophobic chemicals.
Anschutz, P; Budzinski, H; Cachot, J; Deflandre, B; Etcheber, H; LeMenach, K; Leray-Forget, J; Morin, B; Peluhet, L; Vicquelin, L, 2011
)
0.37
" These mechanisms can be associated with the differential susceptibility to the toxic and carcinogenic effects of DMBA observed in these mice."( 7,12-Dimethylbenz(a)anthracene-induced genotoxicity on bone marrow cells from mice phenotypically selected for low acute inflammatory response.
Albuquerque, LL; Borelli, P; Borrego, A; Cabrera, WH; da Silva, GB; De Franco, M; Ibañez, OM; Jensen, JR; Katz, IS; Massa, S; Ribeiro, OG; Starobinas, N; Suppa, AP, 2016
)
0.43
" The mixtures of lindane and DMBA did not produce a synergistic toxic effect on follicles."( Detection of lindane and 7,12-dimethylbenz[a]anthracene toxicity at low concentrations in a three-dimensional ovarian follicle culture system.
Loch-Caruso, R; Shikanov, A; Young, CJ; Zhou, H, 2018
)
0.48
" The aqueous and methanolic broccoli extract supplements ameliorated the adverse effects by increasing the level of GSH, decreasing the MDA level, and reducing DNA fragmentation."( Potential chemopreventive effects of Broccoli extract supplementation against 7, 12 dimethyl Benz(a)anthracene (DMBA) -induced toxicity in female rats.
Abdel-Razek, AS; AbuBakr, HO; Allam, AM; Gouda, EM; Khattab, MS; Mousa, SZ; Yassin, AM, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" These results emphasize the role of the peak concentration of doxorubicin for its maximal action in the target cell."( Cellular pharmacokinetics of doxorubicin in cultured mouse sarcoma cells originating from autochthonous tumors.
Nguyen-Ngoc, T; Robert, J; Vrignaud, P, 1984
)
0.27
" All the measurements yield very similar pharmacokinetic curves."( Fluorescence pharmacokinetics of Lutetium Texaphyrin (PCI-0123, Lu-Tex) in the skin and in healthy and tumoral hamster cheek-pouch mucosa.
Monnier, P; Radu, A; van den Bergh, H; Wagnières, G; Zellweger, M, 2000
)
0.31
" The timing of 24 h after the administration of PF was chosen for the ultrasonic exposure, based on pharmacokinetic analysis of the PF concentrations in the tumor, plasma, skin and muscle."( Sonodynamic therapy on chemically induced mammary tumor: pharmacokinetics, tissue distribution and sonodynamically induced antitumor effect of porfimer sodium.
Okuyama, N; Sasaki, K; Umemura, S; Yumita, N, 2004
)
0.32
" The timing of 24 h after the administration of ATX-70 was chosen for ultrasonic exposure, based on pharmacokinetic analysis of ATX-70 concentrations in the tumor, plasma, skin, and muscle."( Sonodynamic therapy on chemically induced mammary tumor: pharmacokinetics, tissue distribution and sonodynamically induced antitumor effect of gallium-porphyrin complex ATX-70.
Okuyama, N; Sasaki, K; Umemura, S; Yumita, N, 2007
)
0.34
" This study was conducted to investigate the pharmacokinetic interactions between ondansetron and tamoxifen after intravenous and oral administration of ondansetron (both 8 mg/kg) and/or tamoxifen (2 and 10 mg/kg for intravenous and oral administration, respectively), in rats bearing 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammarian tumors (DMBA rats), used as an animal model of human breast cancer."( Pharmacokinetic drug interactions between ondansetron and tamoxifen in female Sprague-Dawley rats with DMBA-induced mammary tumor.
Kim, SH; Lee, MG; Suh, JH; Yang, SH, 2013
)
0.39

Compound-Compound Interactions

ExcerptReferenceRelevance
"The connective tissues underlying the precancerous changes of the epithelia were separated and combined with the epithelia which were separated from the normal mucosa."( [Effect of connective tissues underlying precancerous lesions combined with epithelia separated from normal mucosa].
Cui, XM, 1992
)
0.28
"The effect of interferon (IFN) and tumour necrosis factor (TNF), either alone or combined with hyperthermia, on cell proliferation and expression of idiotype antigen on a murine B-cell lymphoma has been studied."( Changes in the expression of idiotype antigen on murine B-cell lymphoma after hyperthermia alone and in combination with interferon and tumour necrosis factor.
Anderson, RL; Basham, TY; Davies, CD; Hahn, GM, 1990
)
0.28
"This study was conducted to determine the possible carcinogenic role of N-Nitrosonornicotine (NNN) when combined with subcarcinogenic doses of strong carcinogens dimethylbenz (a) anthracene (DMBA) and 4-nitroquinoline-N-oxide (4NQO) in the hamster cheek pouch."( The cancer-promoting effect of N-nitrosonornicotine used in combination with a subcarcinogenic dose of 4-nitroquinoline-N-oxide and 7,12-dimethylbenz (A) anthracene.
Altuwairgi, OS; Doku, HC; Papageorge, MB, 1995
)
0.29
" In the combination with ON, ICI reversed the effect of ON on the progesterone level without influencing the luteinizing hormone and prolactin levels."( Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384.
Michna, H; Nishino, Y; Schneider, MR, 1994
)
0.29
"The effects of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil (UFT) on mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene (DMBA) were investigated in rats."( 1-(2-Tetrahydrofuryl)-5-fluorouracil in combination with uracil suppresses mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene in rats.
Kudo, H; Maemura, M; Mitamura, T; Nakayama, T; Sakamoto, S; Sassa, S; Suzuki, S; Yoshimura, S, 1996
)
0.29
"Tibolone was combined with the antiandrogen flutamide to determine whether the inhibition of tumour growth in the prophylactic 7,12-dimethylbenz(a)anthracene (DMBA) rat model could be attributed to androgenic properties of one of its metabolites."( Tibolone and 5alpha-dihydrotestosterone alone or in combination with an antiandrogen in a rat breast tumour model.
Cremers, EA; de Gooyer, ME; Deckers, GH; Kloosterboer, HJ; van Aalst, GB; Verheul, HA, 2002
)
0.31
" This study was to evaluate the chemopreventive effect of tamoxifen combined with celecoxib, a COX-2 selective inhibitor, on 7,12-dimethylbenz anthracene (DMBA)-induced breast cancer in rats."( [Chemopreventive effect of tamoxifen combined with celecoxib on DMBA-induced breast cancer in rats].
Dai, ZJ; Kang, HF; Liu, XX; Wang, XJ; Xue, FJ; Xue, XH, 2006
)
0.33
" Rats bearing DMBA- or NMU-induced mammary tumors were treated with ON or MEG either alone or in combination with TAM for four weeks."( Potentiation of the antitumor effect of tamoxifen by combination with the antiprogestin onapristone.
Hirtreiter, C; Ishibashi, K; Nishino, T; Nishino, Y, 2009
)
0.35
"Low-intensity ultrasound (LIUS) combined with chemotherapy is an innovative modality for cancer treatment, but its effect on orthotopic carcinoma remains unknown."( Effects of low-intensity ultrasound combined with low-dose carboplatin in an orthotopic hamster model of tongue cancer: A preclinical study.
Cao, W; Chen, H; Hu, Z; Ji, L; Li, HX; Liu, GY; Lv, YK; Yang, D; Zhang, FM; Zheng, JH, 2018
)
0.48
" This study aimed to scrutinize the role of TF alone or combined with doxorubicin (DOX) in 7,12-dimethylbenz(a)anthracene (DMBA)-induced breast carcinoma rat model."( Tenofovir alone or combined with doxorubicin abrogates DMBA-induced mammary cell carcinoma: An insight into its modulatory impact on oxidative/Notch/apoptotic signaling.
Abdеlaziz, RR; Abouelezz, HM; El-Kashef, DH; Nader, MA, 2023
)
0.91
" In parallel, histopathological assessment displayed that mammary glands from animals treated with TF alone or combined with DOX showed better histopathological scores."( Tenofovir alone or combined with doxorubicin abrogates DMBA-induced mammary cell carcinoma: An insight into its modulatory impact on oxidative/Notch/apoptotic signaling.
Abdеlaziz, RR; Abouelezz, HM; El-Kashef, DH; Nader, MA, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" We also undertook a separate bioavailability study using Se-methylselenocysteine, dimethyl selenoxide, and trimethylselenonium as the starting compounds for delivering selenium with one, two, or three methyl groups, and measured the ability of these compounds to restore glutathione peroxidase activity in selenium-depleted animals."( Chemical form of selenium, critical metabolites, and cancer prevention.
Budnick, RM; Ganther, HE; Hayes, C; Ip, C, 1991
)
0.28
" The bioavailability of the Se pool in maintaining liver glutathione peroxidase activity during a period of Se deprivation, following excess selenite or selenomethionine loading, was also assessed."( Tissue selenium levels in selenium-supplemented rats and their relevance in mammary cancer protection.
Hayes, C; Ip, C, 1989
)
0.28
" These highly lipophilic compounds are well absorbed in the intestine."( The influence of bile on the bioavailability of polynuclear aromatic hydrocarbons from the rat intestine.
Barrowman, JA; Rahimtula, A; Rahman, A, 1986
)
0.27
"This study was undertaken to examine intraluminal factors which might alter the bioavailability of an orally ingested hydrocarbon carcinogen, 7,12-dimethylbenz[a]anthracene, and to assess the extent of its enterohepatic circulation."( Studies of the absorption and enterohepatic circulation of 7,12-dimethylbenz[a]anthracene in the rat.
Barrowman, JA; Chernenko, GA; Laher, JM, 1983
)
0.27
" Its high content in soybeans and relatively high bioavailability favor genistein as a promising candidate for the prevention of human cancers."( Antioxidant and antipromotional effects of the soybean isoflavone genistein.
Barnes, S; Bowen, R; Cai, Q; Wang, Y; Wei, H, 1995
)
0.29
" The bioavailability data suggest that the selenium from p-XSC is not as efficiently incorporated into glutathione peroxidase as the selenium from selenite or the other selenocyanate analogs."( Comparative effect of inorganic and organic selenocyanate derivatives in mammary cancer chemoprevention.
el-Bayoumy, K; Ganther, H; Ip, C; Thompson, H; Upadhyaya, P; Vadhanavikit, S, 1994
)
0.29
" The ester linkage of PEG Sorbitan fatty acid esters was hydrolyzed after oral administration, and the PEG Sorbitan moiety was poorly absorbed from the gastrointestinal tract."( Final report on the safety assessment of PEG-6, -8, and -20 sorbitan beeswax.
Lanigan, RS; Yamarik, TA, 2001
)
0.31
" However, RAL, having two hydroxyl moieties, can be conjugated rapidly through phase II metabolism and excreted, making it difficult to achieve adequate bioavailability by oral administration in humans."( Increased antitumor potential of the raloxifene prodrug, raloxifene diphosphate.
Laxmi, YR; Liu, X; Okamoto, K; Okamoto, Y; Sekimoto, M; Shibutani, S; Suzuki, N, 2008
)
0.35
" Morin did not increase AUC or the absolute oral bioavailability (F) for docetaxel after the oral administration of docetaxel in control and DMBA rats with and without morin."( Effects of morin on the pharmacokinetics of docetaxel in rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors.
Kim, SH; Lee, DY; Lee, JH; Lee, MG; Lyuk, KC; Yang, SH, 2011
)
0.37
"Nanochemoprevention has been introduced recently as a novel approach for improving phytochemicals bioavailability and anti-tumor effect."( Chemopreventive efficacy of naringenin-loaded nanoparticles in 7,12-dimethylbenz(a)anthracene induced experimental oral carcinogenesis.
Krishnakumar, N; Manoharan, S; Nirmal, RM; Sulfikkarali, N, 2013
)
0.39
" Many reasons are attributed to this limited success, including inefficient systemic delivery and bioavailability under in vivo conditions."( Synthesis of PLGA nanoparticles of tea polyphenols and their strong in vivo protective effect against chemically induced DNA damage.
Bhatnagar, P; Gupta, KC; Kumar, P; Mishra, S; Shukla, Y; Singh, M; Srivastava, AK, 2013
)
0.39
" In vitro studies were conducted to assess the cellular uptake and bioavailability of the photosensitizer in OSCC cells."( Novel delivery of Chlorin e6 using anti-EGFR antibody tagged virosomes for fluorescence diagnosis of oral cancer in a hamster cheek pouch model.
Bhuvaneswari, R; Bunte, RM; Low, KP; Soo, KC; Thong, PS, 2016
)
0.43
"This study was undertaken to develop and investigate the effect of tamoxifen polymer-lipid hybrid nanoparticles (Tmx-PLN) on its oral bioavailability and efficacy in the 7,12-dimethylbenzanthracene (DMBA)-induced breast cancer model."( Development of Novel Polymer-Lipid Hybrid Nanoparticles of Tamoxifen: In Vitro and In Vivo Evaluation.
Dora, CP; Jena, SK; Pawar, H; Singh, C; Suresh, S; Varthya, M, 2016
)
0.43
" Though, ursolic acid has been shown to have beneficial effects, its poor water solubility and bioavailability hinder to exert its 100% efficacy."( Ursolic acid-loaded chitosan nanoparticles suppress 7,12-dimethylbenz(a)anthracene-induced oral tumor formation through their antilipid peroxidative potential in golden Syrian hamsters.
Karthik, M; Manoharan, S; Muralinaidu, R, 2023
)
0.91

Dosage Studied

Daily intravenous administration of 50 mg/kg cyclosporin A (CsA), after excision of cheek pouch tumors induced with 9,10-dimethyl-1,2-benzanthracene (DMBA), enhanced the incidence of cervical lymph node metastasis to 93%.

ExcerptRelevanceReference
" (2) Determination of the gene dosage for casein mRNA in normal and malignant mammary cells."( Quantitation of casein messenger ribonucleic acid sequences using a specific complementary DNA hybridization probe.
Barker, SW; Rosen, JM, 1976
)
0.26
" These results indicate that dosage may be an important factor in promotion, since several of the tested compounds are known to be promoters in pulmonary and hepatic systems."( Lack of tumor-promoting ability of certain environmental chemicals in a two-stage mouse skin tumorigenesis assay.
Berry, DL; Bracken, WM; DiGiovanni, J; Gleason, GL; Juchau, MR; Slaga, TJ, 1978
)
0.26
"Outbred mice on the 19th-21st day of pregnancy were injected intravenously 3,4-benzpyrene (BP) in the dosage of 15 mg/kg or 9,10-dimethyl-1,2-benzanthracene (DMBA) in the dosage of 40 mg/Kg in control groups, and moreover preliminary injected BP (24 hours before) in experimental groups."( [Acceleration of the metabolism of carcinogens in the maternal body and embryos].
Dikun, PP; Ivanov-Golitsyn, MN; Likhachev, AIa; Napalkov, NP; Shendrikova, IA, 1977
)
0.46
" Dosage was based on Strandqvist's fractionation curve, and compared with nominal standard doses."( Single versus fractionated doses of X-radiation and their effect on mammary carcinoma in the rat.
Horn, H; Horn, Y, 1977
)
0.26
" Tumor growth was measured in the various dosage groups, and at 6 months after tumor induction the animals were sacrificed."( Dose dependence of immunopotentiation and tumor regression induced by levamisole.
Kurtz, BE; Lewis, JD; Metzig, J; Peters, TG; Sampson, D, 1977
)
0.26
" A dose-response relationship was obtained using 4-240 mg/kg of AF-2."( Acute cytogenetic effect of 2-(2-furyl)-3-(5-nitro-2-furyl)-acrylamide (AF-2, a food preservative) on rat bone marrow cells in vivo.
Goto, K; Sugiyama, T; Uenaka, H, 1975
)
0.25
" So 1-thyroxine, depending on the dosage used, may stimulate the development of tumor process in mammary glands, but exert no influence on it (an effect of "the effect extinction"), and finely suppress tumor development."( [The influence of thyroid and antithyroid preparations on the development of induced breast cancer].
Beskrovnyĭ, AM; Sukacheva, OA, 1976
)
0.26
" A similar dose-response relation was observed for the ability of PdiC8 to stimulate epidermal hyperplasia."( Epidermal cell proliferation and promoting ability of phorbol esters.
Scribner, JD; Slaga, TJ; Viaje, A, 1976
)
0.26
" The dose-response curves after treatment with DMBA differed depending on the sampling times, which revealed the difficulty of obtaining accurate dose-response relations in the micronucleus assay."( Micronucleus induction in mouse peripheral reticulocytes by 7,12-dimethylbenz[a]anthracene.
Asita, AO; Hayashi, M; Hiwatashi, T; Kodama, Y; Kurita, M; Matsuoka, A; Ohtsuki, H; Sofuni, T; Suzuki, T; Tamai, K,
)
0.13
"Daily intravenous administration of 50 mg/kg cyclosporin A (CsA), after excision of cheek pouch tumors induced with 9,10-dimethyl-1,2-benzanthracene (DMBA), enhanced the incidence of cervical lymph node metastasis to 93%, a significant increase over the rates observed for animals receiving a dosage of 25 mg/kg (43%), and for control animals receiving no CsA (40%)."( Enhancement by cyclosporin A of metastasis from hamster cheek pouch carcinoma.
Chino, T; Kage, T; Mogi, M; Nakajima, J; Ueda, A; Yamada, T, 1992
)
0.49
" On the basis of a dose-response curve, a dose of 100 micrograms/kg/d of Cetrorelix was determined as sufficient for a full antitumor response."( Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.
Comaru-Schally, AM; Engel, J; Harleman, JH; Hilgard, P; Reissmann, T; Schally, AV, 1992
)
0.28
"8% LA diet group, and a positive dose-response relationship between dietary LA and mammary-tumor incidence was observed."( Differential effects of dietary linoleic acid on mouse skin-tumor promotion and mammary carcinogenesis.
Bechtel, DH; Belury, MA; Fischer, SM; Lee, ML; Leyton, J; Locniskar, M; Maldve, RE; Slaga, TJ, 1992
)
0.28
"The present studies determined the impact of age, dietary selenium and 7,12-dimethylbenz(a)anthracene (DMBA) dosage on the occurrence of DMBA-DNA adducts in rat mammary tissue."( Age, dietary selenium and quantity of 7,12-dimethylbenz(a)anthracene influence the in vivo occurrence of rat mammary DNA adducts.
Liu, JZ; Milner, JA, 1992
)
0.28
" Similar alterations in ras gene dosage have been seen during progression of papillomas to carcinomas in vivo."( Comparison of ras activation during epidermal carcinogenesis in vitro and in vivo.
Balmain, A; Bowden, GT; Haddow, S; Jaffe, D; Jonas, D; Quintanilla, M, 1991
)
0.28
" These studies suggest that while v-H-ras transfection can result in the development of metastatic ability in rat mammary cancer cells, there is no simple dose-response relationship between the level of v-H-ras expression in cloned rat mammary cancer cell transfectants and the development of experimental or spontaneous metastases."( Relationship between metastatic ability and H-ras oncogene expression in rat mammary cancer cells transfected with the v-H-ras oncogene.
Isaacs, JT; Kyprianou, N, 1990
)
0.28
" The dose-response curves for all compounds show a plateau with higher exposures."( Drosophila wing-spot test: improved detectability of genotoxicity of polycyclic aromatic hydrocarbons.
Frölich, A; Würgler, FE, 1990
)
0.28
" The number of colonies which developed during promoter exposure in cocultures showed a dose-response curve which differed from the dose-response curve for stimulation of growth of 308 colonies in the absence of normal keratinocytes."( Development of an in vitro analogue of initiated mouse epidermis to study tumor promoters and antipromoters.
Hennings, H; Jung, R; Michael, DM; Pettit, GR; Robinson, VA; Yuspa, SH, 1990
)
0.28
" We therefore analyzed dose-response relationships for skin tumor promoting activity and the ability to induce epidermal ornithine decarboxylase (ODC) with a series of structurally related quinones."( Epidermal ornithine decarboxylase induction and mouse skin tumor promotion by quinones.
Conti, CJ; DiGiovanni, J; Flynn, LM; Monks, TJ; Walker, SE, 1990
)
0.28
" In order to determine the levels of uptake of DMBA, the glands were exposed to the transforming dosage of the procarcinogen (7."( Fate of 7,12-dimethylbenz(a)anthracene in the mouse mammary gland during initiation and promotion stages of carcinogenesis in vitro.
Baird, WM; Bandyopadhyay, AM; Banerjee, MR; Das, SK; Delp, CR; Mathiesen, M, 1989
)
0.28
" At each fixed frequency of TPA application, there was a good dose-response of TPA in mouse skin papilloma incidence."( Dose and frequency effect in mouse skin tumor promotion.
Becher, H; Chouroulinkov, I; Day, NE; Lasne, C; Lowy, R; Wahrendorf, J; Yamasaki, H, 1989
)
0.28
" The dosage of OHM for inducing a comparable degree of acute and chronic hyperplasia to that induced by mezerein was 3- to 10-fold higher."( Comparison of octahydromezerein and mezerein as protein kinase C activators and as mouse skin tumor promoters.
Blumberg, PM; Hennings, H; Sharkey, NA; Yuspa, SH, 1989
)
0.28
" However, rats fed the high-fat diet showed greater concentrations of radioactivity in the liver, kidney, adrenal, pituitary, breast, and adipose tissue at 4 h after dosing when compared to rats fed low-fat diets."( Hepatic and intestinal drug-metabolizing enzymes and the tissue distribution and excretion of 14C-7,12-dimethylbenz[a]anthracene in rats fed diets varying in fat concentration.
Clinton, SK; Visek, WJ, 1989
)
0.28
" Five of six chemicals tested yielded statistically significant and generally linear dose-response curves."( Assay of mutagens in aqueous fecal extracts with a modified ames Salmonella test.
Andrews, AW; Riggs, CW; Shaw, R, 1985
)
0.27
" Similar dose-response data were obtained at various doses of two promoting agents effective in hepatocarcinogenesis, PB and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), in livers of F-344 female rats following initiation with DEN (10 mg/kg) 24 h post-70% hepatectomy."( A method to quantitate the relative initiating and promoting potencies of hepatocarcinogenic agents in their dose-response relationships to altered hepatic foci.
Campbell, HA; Glauert, HP; Goldsworthy, TL; Kennan, W; Maronpot, RR; Moran, S; Pitot, HC, 1987
)
0.27
" with one 25 mg/kg dose of dimethylnitrosamine (DMN) as neonates or dosed twice orally with 7,12-dimethylbenz[a]anthracene (DMBA) shortly after ovariectomy."( Differential renal tumor response to N-ethylnitrosourea and dimethylnitrosamine in the Nb rat: basis for a new rodent model of nephroblastoma.
Hard, GC, 1985
)
0.27
" Inhibition by topical retinoic acid of ODC induction by TPA was partially overcome in a dose-response fashion by PGE."( The role of prostaglandin E1 in ornithine decarboxylase induction by tumor promoters.
Boutwell, RK; Cleaveland, JS; Ordman, AB; Simsiman, RC, 1986
)
0.27
" This procedure makes possible a dose-response analysis of several tissues under controlled conditions without confounding endogenous vasoregulation."( Vascular reactivity to norepinephrine of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors and normal tissue as studied in vitro.
Hultborn, R; Jansson, I; Tveit, E; Weiss, L, 1986
)
0.27
" These results correlated closely with the dose-response relationships for tumor initiation by the two hydrocarbons."( Correlation between formation of a specific hydrocarbon-deoxyribonucleoside adduct and tumor-initiating activity of 7,12-dimethylbenz(a)anthracene and its 9- and 10-monofluoroderivatives in mice.
DiGiovanni, J; Fisher, EP; Sawyer, TW, 1986
)
0.27
" The SENCAR mouse model provides a good dose-response relationship for many carcinogens used as tumor initiators and for many compounds used as tumor promoter."( SENCAR mouse skin tumorigenesis model versus other strains and stocks of mice.
Slaga, TJ, 1986
)
0.27
" For rats dosed with MNU, relatively few cancers developed either during an extended observation following pregnancy and lactation or following administration of prolactin, a growth stimulator of mammary cancers."( Suppression by pregnancy of chemically induced preneoplastic cells of the rat mammary gland.
Grubbs, CJ; Hill, DL; Juliana, MM; Whitaker, LM,
)
0.13
" Indomethacin, in the dosage administered, was not found to cause regression of established tumors."( The effect of indomethacin on tumor regression in DMBA-induced epithelial neoplasia of hamster cheek pouch mucosa.
Craig, GT; Franklin, CD, 1987
)
0.27
" A similar dose-response relationship for papilloma and carcinoma formation was observed when chrysarobin was applied once weekly."( Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice.
Conti, CJ; DiGiovanni, J; Kruszewski, FH, 1987
)
0.27
" There was an obvious dose-response relationship in the inhibition of epidermal DNA synthesis."( Cell kinetic effects of low doses of the skin carcinogen 7,12-dimethylbenz[a]anthracene on hairless mouse epidermis.
Iversen, OH; Olsen, WM, 1987
)
0.27
"5 micrograms daily dosage significantly increased uterine weights by as much as 10% to 46% after 2 to 4 weeks."( Antimammary carcinogenic activity of 17-alpha-ethinyl estriol.
Lemon, HM, 1987
)
0.27
"7,12-dimethylbenzanthracene (DMBA) is confirmed as active in the mouse bone marrow micronucleus assay 24 hr after dosing as a corn-oil homogenate via either oral gavage or intraperitoneal (ip) injection."( Re-evaluation of the need for multiple sampling times in the mouse bone marrow micronucleus assay: results for DMBA.
Ashby, J; Mirkova, E, 1987
)
0.27
" To test whether immunosuppression mediated by 7,12-dimethylbenz[a]anthracene (DMBA) is regulated by the Ah locus, several endpoints of immune function were measured in Ah-responsive B6C3F1 and Ah-nonresponsive DBA/2N and in Ah-congenic C57BL/6J (responsive B6-AhbAhd and nonresponsive B6-AhdAhd) mice dosed sc with up to 100 micrograms/g DMBA in corn oil."( Immunosuppression following exposure to 7,12-dimethylbenz[a]anthracene (DMBA) in Ah-responsive and Ah-nonresponsive mice.
Cook, JC; Dean, JH; House, RV; Lauer, LD; Thurmond, LM, 1987
)
0.27
" Dose-response parameters for the activation of DMBA by S9 fraction from woodchucks and rats were compared with TA100."( In vitro activation assays with hepatic S9 preparation from wild and laboratory reared woodchucks in the Salmonella mutagenicity test.
Babish, JG; Mumma, RO; Rashid, KA, 1988
)
0.27
" Analyses of dose-response curves suggest (i) CuDIPS preferentially inhibits BP mutagenesis; (ii) the antimutagenic activity of CuDIPS towards DMBA and the cytotoxicity of the copper complex are derived from the DIPS component of the chelate; (iii) the antimutagenic activity of CuDIPS towards BP requires both copper and DIPS; and (iv) DIPS and CuDIPS induced cytotoxicity is required for inhibition of mutagenesis."( Survey of cytotoxicities and antimutagenic and antitumor initiating activities of Cu(II)(3,5-diisopropylsalicylate)2 and its analogs in a keratinocyte-mediated mutation assay and the murine skin multistage carcinogenesis model.
Colby, AB; Reiners, JJ, 1988
)
0.27
" Dose-response data were qualitatively similar among treatment types, with the greatest TBIs in topical ethanol groups and the lowest TBIs in culture medium groups."( 7,12-Dimethylbenz[a]anthracene adduct formation with Syrian hamster cheek pouch epithelial DNA: in vitro studies in organ explant culture.
Coghill, JE; Lurie, AG; Rozenski, DL, 1988
)
0.27
" Overall the results show, in terms of the numbers of animals with tumours, the total numbers of tumours produced and the numbers of malignant tumours formed all in dose-response relationship, that the Swiss mice were the most sensitive and the B57B1/6 mice the least sensitive to the tumour-promoting effects of TPA with the DBA/2 mice occupying and intermediate position."( Sensitivity of the skin of different mouse strains to the promoting effect of 12-0-tetradecanoyl-phorbol-13-acetate.
Chouroulinkov, I; Grover, P; Lasne, C; Phillips, D, 1988
)
0.27
" Similar dose-response curves were observed using either freshly isolated or cryopreserved hepatocytes as activating systems after treatment with DMBA (0."( Promutagen activation by freshly isolated and cryopreserved rat hepatocytes.
Li, AP; Loretz, LJ; Wilson, AG, 1988
)
0.27
" A dose-response relationship was seen after daily oral treatment with complete suppression of tumor growth at doses of 46."( Characterization of the antitumor activity of hexadecylphosphocholine (D 18506).
Berger, MR; Eibl, H; Engel, J; Hilgard, P; Schumacher, W; Stekar, J; Unger, C; Voegeli, R, 1988
)
0.27
" A similar dose-response relationship for papilloma and carcinoma formation was observed when BHTOOH was applied twice weekly for 50 weeks to mice previously initiated with 7,12-dimethylbenz[a]anthracene."( Tumor promotion by a hydroperoxide metabolite of butylated hydroxytoluene, 2,6-di-tert-butyl-4-hydroperoxy-4-methyl-2,5-cyclohexadienone, in mouse skin.
Kensler, TW; Taffe, BG, 1988
)
0.27
" As a criterion of genotoxic effects of the compound, adopted is a significant and reproducible difference of results at least once or a significant increase in the percentage of polychromatic erythrocytes with micronuclei and dose-response relationship."( [Methods used for evaluating mutagenic and genotoxic properties of chemical compounds. I. The micronucleus test in vivo (an abridged version)].
Przybojewska, B, 1988
)
0.27
" It is concluded that, while the priming action exerted by E2B on PgRs might explain the potentiating effect shown by E2B on MPA activity, the synergism observed between TMX and MPA should be explained on an extrareceptorial basis, an induction on PgR synthesis by TMX not being evident at the dosage and priming time employed in this study."( Effects of tamoxifen, estradiol benzoate and medroxyprogesterone acetate on the growth of DMBA-induced rat mammary carcinoma.
Barbi, GP; Boccardo, F; Dandolo, G; De Menech, R; Guarneri, D; Moro, MG; Paganuzzi, M; Pino, G; Sanguineti, M; Zanardi, S, 1985
)
0.27
" These results correlated closely with the dose-response relationships for tumor initiation by the two hydrocarbons."( Covalent binding of 7,12-dimethylbenz(a)anthracene and 10-fluoro-7,12-dimethylbenz(a)anthracene to mouse epidermal DNA and its relationship to tumor-initiating activity.
Aalfs, KK; DiGiovanni, J; Fisher, EP; Prichett, WP, 1985
)
0.27
" These data were then used to separately construct dose-response curves characteristic for DMBA- and N-methylnitrosourea-induced mammary carcinogenesis."( Determination of the number of events required for mammary carcinogenesis in the Sprague-Dawley female rat.
Isaacs, JT, 1985
)
0.27
" Altered expression with each z w+ complex was assayed on the basis of the induction of aberrantly pigmented eye sectors known to be diagnostic of the interaction between z and the dosage of the functionally active w+4."( Misregulation versus mutation in the alteration of gene expression by carcinogens through interactions with transposable elements in Drosophila melanogaster.
Fahmy, MJ; Fahmy, OG, 1983
)
0.27
" The induction of SCEs followed a dose-response pattern with plateaus at high doses of PAH."( Activation of polycyclic hydrocarbons in Reuber H4-II-E hepatoma cells. An in vitro system for the induction of SCEs.
Bynum, G; Dean, RG; Hadley, E; Jacobson-Kram, D, 1983
)
0.27
" Dose-response curves and [3H]thymidine labeling indices showed the antimitotic and cytocidal effects of the drug varied in a dose-dependent fashion."( Doxorubicin-induced ultrastructural and growth changes in primary cultures of 7,12-dimethylbenz[a]anthracene-induced mammary tumors.
Safa, AR; Tseng, MT, 1983
)
0.27
" Seventy-nine rats survived dosing and operation and were observed for 77 weeks."( Breast tumor incidence in rats after partial mammary resection.
Donegan, WL; Klamer, TW; Max, MH, 1983
)
0.27
" Thus far, we have defined dose-response curves for tamoxifen, adriamycin, thiotepa, and methotrexate."( In vitro drug screening and individualized treatment planning for cancer patients.
Safa, AR; Tseng, MT, 1983
)
0.27
" DMBA led to a marked predominance of squamous celled tumours (SQCT) when treatment was potent, while basal celled and adnexal tumours (BCAT) prevailed after any dosage of MCA."( Skin carcinogenesis in rats by 3-methylcholanthrene and 7,12-dimethylbenz(alpha)anthracene. Influence of dose and frequency on tumour response and its histological type.
Arffmann, E; Glenthøj, A; Rasmussen, KS, 1983
)
0.27
" Lengthening the duration of HF diet treatment (0, 3, 6, 16 wk) increased mammary tumor development, suggesting a time dose-response relationship."( Promotion of 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis by high dietary fat in the rat: possible role of intercellular communication.
Aylsworth, CF; Jone, C; Meites, J; Trosko, JE; Welsch, CW, 1984
)
0.27
" Metabolic activation was provided by ferret or rat hepatic S-9 fractions at 5 levels for each chemical, and optimal S-9 levels as well as dose-response curves were obtained."( In vitro activation of the promutagens 2-acetamidofluorene, cyclophosphamide and 7,12-dimethylbenzanthracene by constitutive ferret and rat hepatic S-9 fractions.
Babish, JG; Frederick, KA, 1984
)
0.27
" The 10 micrograms/g dosage resulted in a marked decrease in spleen weights and spleen and bone marrow cellularity, while thymus and body weights were not significantly altered."( Immunosuppression following 7,12-dimethylbenz[a]anthracene exposure in B6C3F1 mice. I. Effects on humoral immunity and host resistance.
Dean, JH; House, RV; Irons, R; Lauer, LD; Murray, MJ; Ward, EC, 1984
)
0.27
" It became shorter with an increase in the dosage and frequency of administration of IAP."( [Effects of immunosuppressive acidic protein on 7, 12-dimethylbenzanthracene (DMBA) induced pancreatic cancer in rats].
Ejiri, T; Kobari, M; Matsuno, S; Yamauchi, H, 1984
)
0.27
" It became shorter with increases in the dosage and frequency of administration of IAP."( Effects of immunosuppressive acidic protein on DMBA-induced pancreatic cancer in rats.
Ejiri, T; Kobari, M; Matsuno, S; Sato, T; Yamauchi, H, 1984
)
0.27
" Dose-response relationships for the radiomimetic activity of phorbol derivatives in HeLa cells (Kinzel et al."( Interaction of phorbol derivatives with replicating cells.
Fürstenberger, G; Goerttler, K; Kinzel, V; Loehrke, H; Marks, F; Richards, J, 1984
)
0.27
" In dose-response studies low doses of the new analogs effected a higher tumor weight inhibition than BCNU in the treatment of subcutaneously implanted Walker 256."( Anticancer activity of new nitrosoureas against Walder carcinosarcoma 256 and DMBA-induced mammary cancer of the rat.
Eisenbrand, G; Fiebig, HH; Zeller, WJ; Zentgraf, R, 1980
)
0.26
" A comparison of the histological structure and histochemical properties of malignant tumors showed their being independent on the chemical structure, dosage and terms of the carcinogen administration."( [Enzymohistochemical study of the tumors from the transplacental and postnatal exposure to various carcinogens].
Kolodin, VI; P''rvanova, LG, 1980
)
0.26
" These results further stress the importance of gene dosage effects, related to the distal part of chromosome 15, in Thy-1-positive T-cell leukemogenesis."( Nonrandom chromosomal changes in thy-1-positive and thy-1-negative lymphomas induced by 7,12-dimethylbenzanthracene in SJL mice.
Babonits, M; Haran-Ghera, N; Klein, G; Ohno, S; Spira, J; Wiener, F; Wirschubski, Z, 1980
)
0.26
" The test chemicals elicited a dose-response with both activating systems."( Comparison of metabolic systems required to activate pro-mutagens/carcinogens in vitro for sister-chromatid exchange studies.
Kaur, P; Sabharwal, PS; Wojciechowski, JP, 1981
)
0.26
" In addition, a steeper slope of the dose-response curve was obtained with YV cells, suggesting a greater susceptibility of YV cells to DMBA."( 7,12-dimethylbenz[a]anthracene-induced DNA binding and repair synthesis in susceptible and nonsusceptible mammary epithelial cells in culture.
Russo, J; Tay, LK, 1981
)
0.26
"The dose-response relationships from the data described in Paper I were analysed."( Initiation and promotion at different ages and doses in 2200 mice. III. Linear extrapolation from high doses may underestimate low-dose tumour risks.
Peto, R; Shubik, P; Stenbäck, F, 1981
)
0.26
" Growth rates, DNA synthesis, and dose-response curves were determined; the toxicity of DMBA was measured by its effect on cell growth."( Influence of age and parity on the susceptibility of rat mammary gland epithelial cells in primary cultures to 7,12-dimethylbenz(a)anthracene.
Russo, IH; Russo, J; Tait, L; Wilgus, G, 1981
)
0.26
" However, dose-response studies with respect to DMBA in the two strains in two-stage carcinogenesis suggested that metabolic activation of DMBA to the active carcinogen was not limiting in the resistant strain."( Two-stage skin carcinogenesis in sensitive and resistant mouse strains.
Ashman, LK; Cook, MG; Kotlarski, I; Murray, AW, 1982
)
0.26
"Double dosing and single sampling seems to be the simplest and most reliable method for detecting clastogens in the mouse peripheral blood micronucleus test."( An optimal, generalized sampling time of 30 +/- 6 h after double dosing in the mouse peripheral blood micronucleus test.
Higashikuni, N; Sutou, S, 1995
)
0.29
" The dosing protocol of DMBA chosen for the magnetic field experiments induced mammary tumors in about 50% of sham-exposed control animals within 3 months after application."( Linear relationship between flux density and tumor co-promoting effect of prolonged magnetic field exposure in a breast cancer model.
Löscher, W; Mevissen, M, 1995
)
0.29
"We investigated the role of dosing regimen on ras mutations in chemically induced CD-1 mouse liver tumors."( Dose-related changes in the profile of ras mutations in chemically induced CD-1 mouse liver tumors.
Hammermeister, CL; Joslyn, DJ; Kraynak, AR; Leander, KR; Ledwith, BJ; Manam, S; Nichols, WW; Prahalada, S; Shinder, GA; van Zwieten, MJ, 1995
)
0.29
" In contrast, the dose-response curve observed for DEN-treated rats 18 weeks after carcinogen administration was similar to that observed 2 weeks after carcinogen treatment for both phenobarbital- and non-phenobarbital-treated rats."( Focal and non-focal hepatic expression of placental glutathione S-transferase in carcinogen-treated rats.
Baker, K; Campbell, HA; Dragan, YP; Mass, M; Pitot, HC; Vaughan, J, 1994
)
0.29
"6 mg/kg of salmon, respectively) or to PCBs at a dosage of 20% of the 96 hr LD50 (54."( Suppression of B-cell mediated immunity in juvenile chinook salmon (Oncorhynchus tshawytscha) after exposure to either a polycyclic aromatic hydrocarbon or to polychlorinated biphenyls.
Arkoosh, MR; Casillas, E; Clemons, E; Myers, M, 1994
)
0.29
" This study was undertaken to see whether replacing 18% of the corn oil (high in linoleic acid) in a 20% fat diet with menhaden oil (high in n-3 fatty acids, low in linoleic acid) or coconut oil (low in n-3 fatty acids, low in linoleic acid), while keeping constant the cholesterol, antioxidant, and total fat content, would affect tumor incidence in virgin female BALB/c mice dosed with DMBA."( Menhaden, coconut, and corn oils and mammary tumor incidence in BALB/c virgin female mice treated with DMBA.
Craig-Schmidt, M; Johnson, J; Lane, HW; Teer, P; White, MT, 1993
)
0.29
" Dose-response studies suggest that like retinoids, glucarate acts directly on tumor cells, rather than having an adjuvant effect."( Mechanism of growth inhibition of mammary carcinomas by glucarate and the glucarate: retinoid combination.
Abou-Issa, H; Curley, RC; Nguyen, MH; Stromberg, PC; Webb, TE,
)
0.13
"Sexually immature rainbow trout were dosed via gavage with 7,12-[14C]dimethylbenz[a]anthracene (DMBA) in order to study hepatic metabolite formation over time and at single and multiple doses."( Time-varying conjugation of 7,12-dimethylbenz[a]anthracene metabolites in rainbow trout (Oncorhynchus mykiss).
O'Connor, JM; Schnitz, AR; Squibb, KS, 1993
)
0.29
" Dose-response studies were conducted at low doses in mouse skin by initiation-promotion and repeated application to compare its activity to that of 7,12-dimethylbenz[a]anthracene (DMBA), benzo[a]pyrene (B[a]P), DB[a,l]P-8,9-dihydrodiol and DB[a,l]P-11,12-dihydrodiol."( Tumor-initiating activity and carcinogenicity of dibenzo[a,l]pyrene versus 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene at low doses in mouse skin.
Cavalieri, EL; Higginbotham, S; Johansson, SL; RamaKrishna, NV; Rogan, EG, 1993
)
0.29
"The question was addressed whether the dose-response relationship derived from a carcinogenicity study can be used for mechanistic interpretation and to what extent the shape of the curve is dependent on the duration of the bioassay and the time of analysis."( Dose-time response in mouse skin tumor induction by 7, 12-dimethylbenz[a]anthracene and 12-O-tetradecanoyl-phorbol-13-acetate.
Beland, PE; Candrian, R; Fekete, T; Fischer, WH; Lutz, WK, 1996
)
0.29
" In vivo experimental animal models provide information not available in human populations; they are adequate for hazard identification, dose-response modeling, exposure assessment, and risk characterization, the four required steps for quantifying the estimated risk of cancer development associated with toxic chemical exposure."( Experimentally induced mammary tumors in rats.
Russo, IH; Russo, J, 1996
)
0.29
" In this report, experiments were carried out in which treatment with the Se-garlic was started after carcinogen dosing (DMBA or MNU) but was restricted to either the early or late stage of neoplastic progression."( Selenium-enriched garlic inhibits the early stage but not the late stage of mammary carcinogenesis.
Ip, C; Lisk, DJ; Thompson, HJ, 1996
)
0.29
" When the classical dosage (1 mg DMBA given once a week for 6 weeks) was split into five daily doses of 200 microg given intragastrically to female SENCAR mice each week for 6 weeks, toxicity was high and the major tumor type seen was lymphoma."( Induction of mammary cancer and lymphoma by multiple, low oral doses of 7,12-dimethylbenz[a]anthracene in SENCAR mice.
Conti, CJ; Johnston, D; LaBate, M; MacLeod, MC; Qing, WG; Slaga, TJ, 1997
)
0.3
" However, the concept of clinical trials requires new approaches to dose finding and response evaluation, because the dose-response relationship of this compound is distinctly different from that of classical cytostatic agents."( D-21266, a new heterocyclic alkylphospholipid with antitumour activity.
Engel, J; Hilgard, P; Klenner, T; Kutscher, B; Nössner, G; Stekar, J, 1997
)
0.3
"Six healthy non-atopic male volunteers participated in a dose-response study of N,N-dimethylbenzylamine (DMBA), which is a reactive chemical used in epoxy systems."( Metachromatic cells and eosinophils in the nasal mucosa and N,N-dimethylbenzylamine exposure.
Akesson, B; Irander, K; Ståhlbom, B; Welinder, H, 1997
)
0.3
" Because IP6 is particularly abundant in the bran part of certain mature seeds such as wheat, we investigated whether a high-fiber bran diet containing high IP6 shows a dose-response inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat mammary carcinogenesis."( Comparison of pure inositol hexaphosphate and high-bran diet in the prevention of DMBA-induced rat mammary carcinogenesis.
Shamsuddin, AM; Vucenik, I; Yang, GY, 1997
)
0.3
" Group A received oral retinamide at a dosage of 20mg/kg, every day for eight weeks."( [Treatment of oral leukoplakia with retinamide].
Liu, X; Shen, S; Sun, Z, 1996
)
0.29
"1 mg/kg, and the clearance half-life of 7-16 h indicated that once-daily dosing would be possible in humans."( The relevance of preclinical models to the treatment of postmenopausal breast cancer.
Dukes, M, 1997
)
0.3
" Using our dosage regimen, 'chemical oophorectomy' with leuprolide was not as effective as surgical oophorectomy in the prevention of chemical carcinogenesis by DMBA but was comparable to the results obtained with tamoxifen."( Prevention of DMBA-induced rat mammary carcinomas comparing leuprolide, oophorectomy, and tamoxifen.
Brackett, DJ; Hanas, JS; Hollingsworth, AB; Lerner, MR; Lightfoot, SA; McCay, PB; Wilkerson, KB, 1998
)
0.3
"0% for 14 days prior to dosing with DMBA exhibited a significant decrease in mammary tumor development, compared with controls."( Effect of the beta-diketones diferuloylmethane (curcumin) and dibenzoylmethane on rat mammary DNA adducts and tumors induced by 7,12-dimethylbenz[a]anthracene.
Fisher, C; Iovinelli, M; MacDonald, C; Singletary, K; Wallig, M, 1998
)
0.3
"In the present study, the cytotoxic effects of Kuwaiti weathered crude oil and a potent carcinogen (DMBA) on rat liver cells were examined by light and electron microscopy at each of 4 sampling periods after the start of low dosing (0."( Cytotoxicity of Kuwait weathered lake crude oil on rat hepatocytes: a histological and ultrastructural study.
Abou-Salem, K; Akbar, L; Meakins, R; Safer, AM, 1998
)
0.3
"The effectiveness of DCT was found to depend on the applied dosage -36 C/cm3 was more effective than 18 C/cm3."( [Direct-current treatment of chemically induced mammary carcinoma in an animal model: MR volumetric assessment of the effect of the therapy].
Fielder, K; Gossmann, A; Heindel, W; Krüger, K; Kugel, H; Lackner, K; Li, B; Raab, M; Schäfer, H, 1998
)
0.3
" Papules were first detected in DMBA-initiated mice 21 days after the start of dosing with TPA."( Squamous cell hyperplastic foci: precursors of cutaneous papillomas induced in SENCAR mice by a two-stage carcinogenesis regimen.
Binder, RL; Conti, CJ; Gallagher, PM; Johnson, GR; Stockman, SL; Sundberg, JP, 1998
)
0.3
" TNF-alpha(-/-) mice were resistant to development of benign and malignant skin tumors, whether induced by initiation with DMBA and promotion with TPA or by repeated dosing with DMBA."( Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis.
Arnott, C; Balkwill, F; Burke, F; East, N; Holdsworth, H; Kollias, G; Moore, RJ; Owens, DM; Pasparakis, M; Rollins, B; Stamp, G; Turner, L, 1999
)
0.3
" Primordial follicle destruction is known to result from dosing of mice and rats with three polycyclic aromatic hydrocarbons (PAHs), contaminants commonly found in cigarette smoke."( Ovotoxicity in female Fischer rats and B6 mice induced by low-dose exposure to three polycyclic aromatic hydrocarbons: comparison through calculation of an ovotoxic index.
Borman, SM; Christian, PJ; Hoyer, PB; Sipes, IG, 2000
)
0.31
" Further experiments using a full time course, dose-response and methods to confirm that AhR is a direct mediator of these effects are required."( Effect of beta-naphthoflavone and dimethylbenz[a]anthracene on apoptosis and HSP70 expression in juvenile channel catfish (Ictalurus punctatus) ovary.
Janz, DM; Weber, LP, 2001
)
0.31
" They also received the experimental diet containing 25 to 250 ppm 4-NP or GS for 50 weeks, starting one week after the dosing of DMBA."( Inhibitory effects of estrogenic compounds, 4-nonylphenol and genistein, on 7,12-dimethylbenz[a]anthracene-induced ovarian carcinogenesis in rats.
Kohno, H; Tanaka, T; Tanino, M; Yanaida, Y, 2002
)
0.31
" Hence, to verify a biphasic dose-response relationship (enhancement of carcinogenesis at low dose, and inhibition at high dose), we investigated the effects of prenatal exposure to PCB126 on mammary gland differentiation."( Mammary gland differentiation in female rats after prenatal exposure to 3,3',4,4',5-pentachlorobiphenyl.
Furusato, M; Hano, H; Imano, N; Masaoka, T; Muto, T; Nakaaki, K; Takahashi, H; Wakui, S, 2002
)
0.31
" In a second dose-response study, orally administered isopimpinellin (35, 70 and 150 mg/kg) blocked DMBA-DNA adduct formation by 23, 56 and 69%, respectively."( Oral administration of the citrus coumarin, isopimpinellin, blocks DNA adduct formation and skin tumor initiation by 7,12-dimethylbenz[a]anthracene in SENCAR mice.
DiGiovanni, J; Kleiner, HE; Reed, MJ; Starost, MF; Vulimiri, SV, 2002
)
0.31
" Therefore, a gene dosage problem related to the mutant N-ras gene is involved in development of leukemia."( 7,12-DMBA-induced rat leukemia: a review with insights into future research.
Koami, K; Maeda, S; Osaka, M; Sugiyama, T; Ueda, N, 2002
)
0.31
" No papillomas or any other skin lesions were observed in age- and sex-matched VDR(+/+) mice dosed with DMBA and followed for 6 months."( Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis.
Sundberg, JP; Welsh, J; Zinser, GM, 2002
)
0.31
" Mice were dosed three cycles of 5 days/week with DMBA in corn oil orally."( CYP1B1 determines susceptibility to low doses of 7,12-dimethylbenz[a]anthracene-induced ovarian cancers in mice: correlation of CYP1B1-mediated DNA adducts with carcinogenicity.
Buters, J; Gonzalez, FJ; Greim, H; Hintermair, J; Quintanilla-Martinez, L; Schober, W; Soballa, VJ; Wolff, T, 2003
)
0.32
"The earlier tumor development in p53-deficient mice provides the in vivo evidence that reduction of p53 dosage or possibly p53 haploinsufficiency might be sufficient to promote salivary gland tumorigenesis."( Reduction of p53 dosage renders mice hypersensitive to 7, 12-dimethylbenz(alpha) anthracene-induced salivary gland tumorigenesis.
Ide, F; Kitada, M; Kusama, K; Sakashita, H,
)
0.13
" They also received the experimental diet containing 5, 50 or 500 ppm atrazine for 50 weeks, starting one week after the dosing of DMBA."( Lack of modifying effects of an estrogenic compound atrazine on 7,12-dimethylbenz(a)anthracene-induced ovarian carcinogenesis in rats.
Kohno, H; Sugie, S; Suzuki, R; Tanaka, T, 2004
)
0.32
"We evaluated the dose-response effect of tomato paste on 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster buccal pouch (HBP) carcinogenesis using lipid peroxidation, reduced glutathione (GSH) and the GSH-dependent enzymes; glutathione peroxidase (GPx), glutathione-S-transferase (GST) and gamma-glutamyltranspeptidase (GGT) as biomarkers of chemoprevention."( Dose-response effect of tomato paste on 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis.
Bhuvaneswari, V; Nagini, S; Velmurugan, B, 2004
)
0.32
" Fetal sensitivity and dose-response characteristics with regard to transplacental mutagenesis by these compounds have never been quantified."( The mutagenic effects of 7,12-dimethylbenz[a]anthacene, 3-methylcholanthrene and benzo[a]pyrene to the developing Syrian hamster fetus measured by an in vivo/in vitro mutation assay.
Donovan, PJ; Nardone, R; Smith, GT, 2004
)
0.32
" Also, TAS-108 strongly inhibited tumor growth in dimethylbenzanthracene-induced mammary carcinomain the rat, the endogenous E2 model, at a dosage of 1 to 3 mg/kg/day."( TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
Aoyagi, Y; Asao, T; Buzdar, AU; Hashimoto, A; Sato, K; Shibata, J; Terada, T; Wierzba, K; Yamamoto, Y; Yano, S; Yonekura, K, 2005
)
0.33
" Ospemifene (N = 18), tamoxifen (N = 20) and raloxifene (N = 17), each dosed at 50 mg/kg, were administered daily by oral gavage, in combination with 20 microg DMBA for the first 6 weeks."( Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice.
Beckett, LA; Degregorio, MW; Gregg, JP; Marchisano-Karpman, C; Read, KC; Wurz, GT; Yu, Q, 2005
)
0.33
" In a 6 week dose-response study of select NOCs and 7,8-benzoflavone (a potent P4501 inhibitor that had little effect on GSTs), DMBA-DNA adduct formation was inhibited by 0, 43 and 24% in the limettin groups; by 26, 26 and 69% in the isopimpinellin groups; and by 80, 96 and 97% in the 7,8- benzoflavone groups at 35, 70 and 150 mg/kg, respectively."( Naturally occurring coumarins inhibit 7,12-dimethylbenz[a]anthracene DNA adduct formation in mouse mammary gland.
Campbell, CT; Kleiner, HE; Prince, M; Robertson, TA; Wells, AJ, 2006
)
0.33
" KA was administered at the dosage level of 100, 200, 300, 400 and 500 mg/kg body weight (BW) in olive oil orally for 14 d, after the induction period is completed (90 d)."( Anticancer effect of Kalpaamruthaa on mammary carcinoma in rats with reference to glycoprotein components, lysosomal and marker enzymes.
Sachdanandam, P; Shanthi, P; Veena, K, 2006
)
0.33
" Rats are exposed to repeated daily dosing (20 days) with 4-vinylcyclohexene diepoxide (VCD) to cause early ovarian failure (model for postmenopause), and ovaries are directly exposed to 7,12-dimethylbenz(a)anthracene (DMBA) to cause abnormal ovarian proliferation and neoplasia."( Dual modality imaging of a novel rat model of ovarian carcinogenesis.
Barton, JK; Brewer, M; Hoyer, PB; Kanter, EM; Marion, SL; Walker, RM,
)
0.13
" mirifica tuberous powder at a dosage of 0, 10, 100 and 1000 mg/kg BW/day for four consecutive weeks."( Pretreatment with phytoestrogen-rich plant decreases breast tumor incidence and exhibits lower profile of mammary ERalpha and ERbeta.
Cherdshewasart, W; Panriansaen, R; Picha, P, 2007
)
0.34
" None of the above findings in RF-exposed animals produced a clear dose-response relation and the responses of the cage-control group were either similar to or stronger than those of any of the RF-exposed group."( Study on potential effects of "902-MHz GSM-type Wireless Communication Signals" on DMBA-induced mammary tumours in Sprague-Dawley rats.
Frauscher, M; Hruby, R; Kuster, N; Neubauer, G, 2008
)
0.35
" Pregnant mice dosed with 1 microg/kg of TCDD or vehicle on gestational day 12."( Mouse breast cancer model-dependent changes in metabolic syndrome-associated phenotypes caused by maternal dioxin exposure and dietary fat.
Baston, DS; Birnbaum, LS; Denison, MS; La Merrill, M; Pomp, D; Threadgill, DW, 2009
)
0.35
"Three and 6 months following VCD dosing there was a significant reduction of ovarian weight and follicle number."( Ovarian neoplasm development by 7,12-dimethylbenz[a]anthracene (DMBA) in a chemically-induced rat model of ovarian failure.
Barton, JK; Bedrnicek, JB; Brewer, MA; Christian, PJ; Davis, JR; Hoyer, PB; Marion, SL, 2009
)
0.35
"Recent clinical trials show that combined oral dosing with estrogen and progestin increases the incidence of breast cancer in postmenopausal women."( Synthetic progestins differentially promote or prevent 7,12-dimethylbenz(a)anthracene-induced mammary tumors in sprague-dawley rats.
Benakanakere, I; Besch-Williford, C; Carroll, CE; Hyder, SM, 2010
)
0.36
" Therefore, the present study was designed to evaluate the effect of combined dosage of celecoxib and fish oil in experimental mammary carcinogenesis."( Evaluation of the role of oxidative stress in chemopreventive action of fish oil and celecoxib in the initiation phase of 7,12-dimethyl benz(α)anthracene-induced mammary carcinogenesis.
Aggarwal, R; Agnihotri, N; Kansal, S; Kaur, R; Negi, AK; Sarotra, P; Sharma, G, 2011
)
0.37
" This study indicates that ACRH extract could be a promising skin tumor promotion suppressing agent at a lower dosage (30 mg/kg)."( Suppression of DMBA/croton oil-induced mouse skin tumor promotion by Ardisia Crispa root hexane extract.
Fezah, O; Roslida, A; Yeong, LT, 2011
)
0.37
"The present study thus demonstrates that the anti-tumor effect of the chemopreventive potential of ACRH is at a lower dosage (30 mg/kg bwt) in both the initiating and promotion period, yet it exhibits a promoting effect at a higher dosage (300 mg/kg bwt)."( Anti-tumor effect of Ardisia crispa hexane fraction on 7, 12-dimethylbenz[α]anthracene-induced mouse skin papillomagenesis.
Hamid, RA; Othman, F; Sulaiman, H; Ting, YL,
)
0.13
"A mouse model of ovarian cancer was created by dosing with 4-vinylcyclohexene diepoxide, which induces follicular apoptosis (simulating menopause), and 7,12-dimethylbenz[a]anthracene, a known carcinogen."( Two-photon excited fluorescence imaging of endogenous contrast in a mouse model of ovarian cancer.
Barton, JK; Brewer, MA; Hoyer, PB; Marion, SL; Rice, PF; Utzinger, U; Watson, JM, 2013
)
0.39
" The altered levels of the above-mentioned biochemical parameters in cancer-bearing animals were significantly ameliorated by the administration of hesperidin at the dosage of 30 mg/kg bw for 45 days."( Modulating effects of hesperidin on key carbohydrate-metabolizing enzymes, lipid profile, and membrane-bound adenosine triphosphatases against 7,12-dimethylbenz(a)anthracene-induced breast carcinogenesis.
Balamurugan, A; Balasubramanian, MP; Nandakumar, N; Rengarajan, T, 2014
)
0.4
" There was an increasing trend of apoptotic index (AI) seen in TH-treated groups with increasing dosage of Tualang Honey, however, the mean AI values of all TH-treated groups were not significantly different from the Control value (p>0."( Inhibitory effects of Tualang Honey on experimental breast cancer in rats: a preliminary study.
Kadir, EA; Othman, NH; Sulaiman, SA; Yahya, NK, 2013
)
0.39
" Therefore, the present study was designed to investigate the effect of combined dosage of celecoxib and n-3 PUFA-rich fish oil in experimental mammary carcinogenesis."( Alteration in apoptosis and cell cycle by celecoxib and/or fish oil in 7,12-dimethyl benzene (α) anthracene-induced mammary carcinogenesis.
Agnihotri, N; Bhatnagar, A; Kansal, S; Negi, AK, 2013
)
0.39
" Although no clear dose-response relationship was observed, folic acid supplementation significantly promoted the progression of the sentinel mammary tumors and was associated with significantly higher sentinel mammary tumor weight and volume compared with the control diet."( Folic acid supplementation promotes mammary tumor progression in a rat model.
Croxford, R; Deghan Manshadi, S; Ishiguro, L; Kim, YI; Medline, A; Renlund, R; Sohn, KJ, 2014
)
0.4
" A subset of 18 wk old mice (lean and obese) were dosed with sesame oil or DMBA (1mg/kg; ip) for 14days and ovaries collected 3days thereafter."( Impact of obesity on 7,12-dimethylbenz[a]anthracene-induced altered ovarian connexin gap junction proteins in female mice.
Ganesan, S; Keating, AF; Nteeba, J, 2015
)
0.42
"Cg-Ay/J heterozygote (obese) mice were dosed with sesame oil or DMBA (1mg/kg; intraperitoneal injection) at 18weeks of age, for 14days."( Enhanced susceptibility of ovaries from obese mice to 7,12-dimethylbenz[a]anthracene-induced DNA damage.
Ganesan, S; Keating, AF; Nteeba, J, 2014
)
0.4
" Mammary tumors were harvested from our previous study in which TPE (50-200 mg/kg) was found to inhibit mammary tumorigenesis in a dose-response manner."( Trianthema portulacastrum Linn. displays anti-inflammatory responses during chemically induced rat mammary tumorigenesis through simultaneous and differential regulation of NF-κB and Nrf2 signaling pathways.
Bishayee, A; Mandal, A, 2015
)
0.42
"This study evidenced that TQF, particularly at its lower dosage (10 mg/kg), ameliorated DMBA/TPA-induced mouse skin tumorigenesis."( Low dose triterpene-quinone fraction from Ardisia crispa root precludes chemical-induced mouse skin tumor promotion.
Abdul Hamid, R; Khaza'ai, H; Mohtarrudin, N; Saiful Yazan, L; Yeong, LT, 2015
)
0.42
"0 g/kg) exhibited inhibition of mammary tumorigenesis in a dose-response manner."( Mechanism of Breast Cancer Preventive Action of Pomegranate: Disruption of Estrogen Receptor and Wnt/β-Catenin Signaling Pathways.
Bishayee, A; Mandal, A, 2015
)
0.42
"6 mg/mL JEKHT reversed their TAM resistance in dose-response studies in vitro."( Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model.
Carney, E; Clarke, R; De Oliveira Andrade, F; FitzGerald, K; Hilakivi-Clarke, L; Hu, R; Yu, W; Zhang, X, 2019
)
0.51
" This study aims to investigate the proper dosage and induction time of DMBA for rat models of SBOTs, and explore their morphological features demonstrated by magnetic resonance (MR) imaging and molecular genetic characteristics."( A rat model of serous borderline ovarian tumors induced by 7,12-dimethylbenz[a]anthracene.
Cai, SQ; Li, X; Li, Y; Li, YA; Qiang, JW; Wang, L; Zhao, SH; Zhu, J, 2019
)
0.51
" The mammary carcinogenesis was produced through a single dosage of DMBA (20 mg/kg bwt) mixed in soya oil (1 mL) administrated intragastrically with a gavage."( Zingerone induced caspase-dependent apoptosis in MCF-7 cells and prevents 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in experimental rats.
Gan, H; Mohan, SK; Veeraraghavan, VP; Xie, X; Zhang, Y; Zheng, L; Zhou, Q, 2019
)
0.51
" Orally treated mangiferin at an effective dosage of 50 mg/kg bw, to DMBA painted hamsters were significantly averted the body weight, succession of tumour, the biochemical as well as histopathological changes."( Modulator effect of mangiferin on biochemical characterization in 7,12-dimethylbenz[a]anthracene induced oral cancer in experimental hamsters.
Liu, M; Pan, S; Wen, C, 2021
)
0.62
" leaves extract significantly reduced 8-OHdG in cultured human lymphocytes in a dose-response manner (P<0."( Anticancer and antimutagenic activity of Silybum marianum L. and Eucalyptus camaldulensis Dehnh. against skin cancer induced by DMBA: In vitro and in vivo models.
A Abu-Siniyeh, A; F Khabour, O; H Alzoubi, K; M Mhaidat, N; S Alkofahi, A, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tetraphenes
ortho-fused polycyclic arene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (87)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency2.81840.044717.8581100.0000AID485294
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency79.43280.631035.7641100.0000AID504339
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
LuciferasePhotinus pyralis (common eastern firefly)Potency21.65790.007215.758889.3584AID1224835; AID588342
acid sphingomyelinaseHomo sapiens (human)Potency25.118914.125424.061339.8107AID504937
pregnane X receptorRattus norvegicus (Norway rat)Potency24.70280.025127.9203501.1870AID651751
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency52.65673.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency21.51820.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency25.97060.173734.304761.8120AID1346859; AID1346924; AID1347035
ATAD5 protein, partialHomo sapiens (human)Potency15.46910.004110.890331.5287AID504466; AID504467
SMAD family member 3Homo sapiens (human)Potency25.97060.173734.304761.8120AID1346859; AID1346924; AID1347035
TDP1 proteinHomo sapiens (human)Potency18.84520.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency20.27140.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency16.59320.000221.22318,912.5098AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency17.78280.707912.194339.8107AID720542
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency44.66840.00137.762544.6684AID2120
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency21.76470.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency20.73120.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency5.45340.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency34.82420.000214.376460.0339AID588532; AID588533; AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency21.71650.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency11.24540.000817.505159.3239AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency39.64170.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency42.11180.375827.485161.6524AID588526; AID588527; AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency24.98890.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency22.06510.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID588513; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
glucocerebrosidaseHomo sapiens (human)Potency10.00000.01268.156944.6684AID2101
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency39.81070.707936.904389.1251AID504333
P53Homo sapiens (human)Potency50.11870.07319.685831.6228AID504706
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency24.79170.001024.504861.6448AID588534; AID588535; AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency32.19260.001019.414170.9645AID588536; AID588537; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency23.21970.023723.228263.5986AID588541; AID743222; AID743223; AID743241
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency28.18380.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency21.86780.000723.06741,258.9301AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency16.27550.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency24.95430.001628.015177.1139AID1224843; AID1224895
activating transcription factor 6Homo sapiens (human)Potency50.33900.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency48.869619.739145.978464.9432AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency3.24420.057821.109761.2679AID1159526; AID1159528
Caspase-7Cricetulus griseus (Chinese hamster)Potency67.89270.006723.496068.5896AID1346980
serine-protein kinase ATM isoform aHomo sapiens (human)Potency17.78280.707925.111941.2351AID485349
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency12.58930.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency31.70470.010039.53711,122.0200AID588545; AID588547
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency10.00003.548119.542744.6684AID743266
caspase-3Cricetulus griseus (Chinese hamster)Potency67.89270.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency33.10360.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency52.10390.042027.378961.6448AID743210; AID743228
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID995
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency34.89374.466824.832944.6684AID651749
ras-related protein Rab-9AHomo sapiens (human)Potency3.16230.00022.621531.4954AID485297
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency27.50760.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency11.22020.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency11.22020.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency11.22020.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency19.95260.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency6.07910.004611.374133.4983AID624296; AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.58930.031610.279239.8107AID884; AID885
caspase-1 isoform alpha precursorHomo sapiens (human)Potency31.62280.000311.448431.6228AID900
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency4.32770.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency44.43210.002319.595674.0614AID651631; AID651743; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency4.32770.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency13.33320.026622.448266.8242AID651802
Caspase-7Homo sapiens (human)Potency31.62283.981118.585631.6228AID889
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency61.18770.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency61.18770.011912.222168.7989AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (166)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (50)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID200693Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA 100 strain) in absence of S9 fraction; - indicates no mutagenic response1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene.
AID200694Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA 100 strain) in presence of S9 fraction1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene.
AID200697Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA 98 strain) in presence of S9 fraction1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene.
AID200696Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA 98 strain) in absence of S9 fraction; - indicates no mutagenic response1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene.
AID200699Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA1537 strain) in absence of S9 fraction; - indicates no mutagenic response1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene.
AID200700Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA1537 strain) in presence of S9 fraction1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,691)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902475 (43.49)18.7374
1990's1309 (23.00)18.2507
2000's1028 (18.06)29.6817
2010's767 (13.48)24.3611
2020's112 (1.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.30 (24.57)
Research Supply Index8.70 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (0.17%)5.53%
Reviews166 (2.76%)6.00%
Case Studies3 (0.05%)4.05%
Observational0 (0.00%)0.25%
Other5,831 (97.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]